<DOC>
	<DOCNO>NCT01464047</DOCNO>
	<brief_summary>The purpose post-marketing surveillance investigate confirm type incidence newly identify adverse event factor affect safety efficacy Sprycel® regulatory authority manage marketing approval properly .</brief_summary>
	<brief_title>Korean Post-marketing Surveillance Sprycel®</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Newly diagnose Philadelphia chromosomepositive ( Ph+ ) chronic myeloid leukemia ( CML ) chronic phase Adults chronic , accelerate , myeloid lymphoid blast phase Ph+ CML resistance intolerance prior therapy include Imatinib Adults Philadelphia chromosomepositive acute lymphoblastic leukemia ( Ph+ALL ) resistance intolerance prior therapy According Warning/Caution local label</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>